Arvind Gulbake

2.0k total citations · 1 hit paper
49 papers, 1.4k citations indexed

About

Arvind Gulbake is a scholar working on Pharmaceutical Science, Molecular Biology and Biomaterials. According to data from OpenAlex, Arvind Gulbake has authored 49 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pharmaceutical Science, 18 papers in Molecular Biology and 18 papers in Biomaterials. Recurrent topics in Arvind Gulbake's work include Nanoparticle-Based Drug Delivery (16 papers), Advanced Drug Delivery Systems (13 papers) and RNA Interference and Gene Delivery (12 papers). Arvind Gulbake is often cited by papers focused on Nanoparticle-Based Drug Delivery (16 papers), Advanced Drug Delivery Systems (13 papers) and RNA Interference and Gene Delivery (12 papers). Arvind Gulbake collaborates with scholars based in India, Finland and United States. Arvind Gulbake's co-authors include Sanjay Jain, Satish Shilpi, Pooja Hurkat, Shivaji Kashte, Ashim Gupta, Saadiq F. El‐Amin, Aviral Jain, Ashish Jain, Ankit Jain and Piush Khare and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Controlled Release and Nanoscale.

In The Last Decade

Arvind Gulbake

47 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

COVID-19 vaccines: rapid development, implications, challenges and future prospects

2021 254 citations Arvind Gulbake et al. profile →

Peers

Countries citing papers authored by Arvind Gulbake

Since Specialization

Citations

This map shows the geographic impact of Arvind Gulbake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arvind Gulbake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arvind Gulbake more than expected).

Fields of papers citing papers by Arvind Gulbake

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arvind Gulbake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arvind Gulbake. The network helps show where Arvind Gulbake may publish in the future.

Co-authorship network of co-authors of Arvind Gulbake

This figure shows the co-authorship network connecting the top 25 collaborators of Arvind Gulbake. A scholar is included among the top collaborators of Arvind Gulbake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arvind Gulbake. Arvind Gulbake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Navigating tumor microenvironment with TME-responsive nanocarriers: Strategies for targeted drug delivery in solid tumor 2025 ·Journal of Drug Delivery Science and Technology ·(unknown), (unknown), Arvind Gulbake	2
2	Dual Drug Loaded Topical Cubosomal Gel Against Candida Albicans: An In Vitro and In Vivo Proof of Concept 2025 ·AAPS PharmSciTech ·Anirudh Nath, Klaudi K. Vaiphei, (unknown), (unknown), (unknown), (unknown), Dipanjan Ghosh, Kuldeep K. Bansal, Arvind Gulbake	2
3	Co-delivery of Doxorubicin and VEGF siRNA using carcinoembryonic antigen-targeted chitosan nanoparticles for colorectal cancer 2024 ·Journal of Drug Delivery Science and Technology ·(unknown), (unknown), (unknown), (unknown), Meghnad G. Joshi, Arvind Gulbake	2
4	Nanomedicine for colon-targeted drug delivery: strategies focusing on inflammatory bowel disease and colon cancer 2024 ·Nanomedicine ·(unknown), Klaudi K. Vaiphei, Naveen Singh, (unknown), Shivani Rai Paliwal, Rishi Paliwal, Arvind Gulbake	6
5	Recent Advances in the Use of Cubosomes as Drug Carriers with Special Emphasis on Topical Applications 2024 ·SHILAP Revista de lepidopterología ·Anirudh Nath, Prashant Dubey, (unknown), Klaudi K. Vaiphei, Jessica M. Rosenholm, Kuldeep K. Bansal, Arvind Gulbake	13
6	A poly-δ-decalactone (PDL) based nanoemulgel for topical delivery of ketoconazole and eugenol against Candida albicans 2024 ·Nanoscale Advances ·Prashant Dubey, (unknown), Klaudi K. Vaiphei, (unknown), (unknown), Carl‐Eric Wilén, Jessica M. Rosenholm, Kuldeep K. Bansal, (unknown), Dipanjan Ghosh, Arvind Gulbake	4
7	A nanotechnology driven effectual localized lung cancer targeting approaches using tyrosine kinases inhibitors: Recent progress, preclinical assessment, challenges, and future perspectives 2024 ·International Journal of Pharmaceutics ·(unknown), Klaudi K. Vaiphei, Arvind Gulbake	4
8	QbD-driven RP-HPLC method for novel chemo-herbal combination, in-silico, force degradation studies, and characterization of dual drug-loaded polymeric and lipidic nanocarriers 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Pramod Kumar, Arvind Gulbake	6
9	Development and In-Vitro Evaluation of Eugenol-Based Nanostructured Lipid Carriers for Effectual Topical Treatment Against C. albicans 2023 ·Journal of Pharmaceutical Sciences ·(unknown), (unknown), Anirudh Nath, Anshu Gupta, Sudhagar Selvaraju, (unknown), (unknown), Arvind Gulbake	9
10	Lentinan: An unexplored novel biomaterial in drug and gene delivery applications 2023 ·Journal of Controlled Release ·(unknown), Rishi Paliwal, Arvind Gulbake	18
11	Insight to drug delivery aspects for colorectal cancer 2016 ·World Journal of Gastroenterology ·Arvind Gulbake	123
12	Development of liposomes entrapped in alginate beads for the treatment of colorectal cancer 2015 ·International Journal of Biological Macromolecules ·Divya Bansal, Arvind Gulbake, Jyoti Kumar Tiwari, Sanjay Jain	48
13	Development and Validation of the HPLC Method for Simultaneous Estimation of Paclitaxel and Topotecan 2013 ·Journal of Chromatographic Science ·Ankit Jain, Arvind Gulbake, Satish Shilpi, Pooja Hurkat, Sushil K. Kashaw, Sanjay Jain	32
14	Insulin delivery through nasal route using thiolated microspheres 2013 ·Drug Delivery ·(unknown), Ashish Jain, Aviral Jain, Satish Shilpi, Arvind Gulbake, Pooja Hurkat, Sanjay Jain	14
15	Chitosan: a potential polymer for colon-specific drug delivery system 2012 ·Expert Opinion on Drug Delivery ·Arvind Gulbake, Sanjay Jain	61
16	Development of surface-functionalised nanoparticles for FGF2 receptor-based solid tumour targeting 2011 ·Journal of Microencapsulation ·Amit Jain, Arvind Gulbake, Ashish Jain, Satish Shilpi, Pooja Hurkat, Aviral Jain, Sanjay Jain	13
17	Mannosylated liposomes bearing Amphotericin B for effective management of visceral Leishmaniasis 2011 ·Journal of Liposome Research ·(unknown), Ashish Jain, Arvind Gulbake, Satish Shilpi, Piush Khare, Aviral Jain, Sanjay Jain	26
18	Chondroitin sulfate functionalized liposomes for solid tumor targeting 2010 ·Journal of drug targeting ·(unknown), Divya Bansal, Arvind Gulbake, Aviral Jain, Vandana Soni, Sanjay Jain	28
19	Potential Approaches for Drug Delivery to the Brain: Past, Present, and Future 2010 ·Critical Reviews in Therapeutic Drug Carrier Systems ·Vandana Soni, Anekant Jain, Piush Khare, Arvind Gulbake, Sanjay Jain	24
20	Targeted delivery of an anti-cancer agent via steroid coupled liposomes 2009 ·Drug Delivery ·(unknown), Arvind Gulbake, Aviral Jain, Suresh P. Vyas, Sanjay Jain	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact